Boevers Emily, McDowell Bradley D, Mott Sarah L, Button Anna M, Lynch Charles F
Carver College of Medicine, University of Iowa, Iowa City, IA 52242, USA.
Holden Comprehensive Cancer Center Population Research Core, University of Iowa, Iowa City, IA 52242, USA.
J Cancer Epidemiol. 2017;2017:4354592. doi: 10.1155/2017/4354592. Epub 2017 Apr 10.
. The study objective was to determine how insurance status relates to treatment receipt and overall survival for patients with early-stage pancreatic exocrine carcinoma. . SEER data were evaluated for 17,234 patients diagnosed with Stage I/II pancreatic exocrine carcinoma. Multivariate regression models controlled for personal characteristics to determine whether insurance status was independently associated with overall survival and receipt of radiation/surgery. . Odds of receiving radiation were 1.50 and 1.75 times higher for insured patients compared to Medicaid and uninsured patients, respectively ( < 0.01). Insured patients had 1.68 and 1.57 times increased odds of receiving surgery compared to Medicaid and uninsured patients ( < 0.01). Risk of death was 1.33 times greater ( < 0.01) in Medicaid patients compared to insured patients; when further adjusted for treatment, the risk of death was attenuated but remained significant (HR = 1.16, < 0.01). Risk of death was 1.16 times higher for uninsured patients compared to insured patients ( = 0.02); when further adjusted for treatment, the risk of death was no longer significant (HR = 1.01, = 0.83). . Uninsured and Medicaid-insured patients experience lower treatment rates compared to patients who have other insurances. The increased likelihood of treatment appears to explain the insured group's survival advantage.
该研究的目的是确定保险状况与早期胰腺外分泌癌患者的治疗接受情况及总生存率之间的关系。对监测、流行病学和最终结果(SEER)数据库中17234例诊断为I/II期胰腺外分泌癌的患者数据进行了评估。多变量回归模型对个人特征进行了控制,以确定保险状况是否与总生存率及放疗/手术的接受情况独立相关。与医疗补助患者和未参保患者相比,参保患者接受放疗的几率分别高出1.50倍和1.75倍(P<0.01)。与医疗补助患者和未参保患者相比,参保患者接受手术的几率分别增加了1.68倍和1.57倍(P<0.01)。与参保患者相比,医疗补助患者的死亡风险高出1.33倍(P<0.01);在进一步对治疗进行调整后,死亡风险有所降低但仍具有显著性(风险比=1.16,P<0.01)。与参保患者相比,未参保患者的死亡风险高出1.16倍(P=0.02);在进一步对治疗进行调整后,死亡风险不再具有显著性(风险比=1.01,P=0.83)。与拥有其他保险的患者相比,未参保和参加医疗补助保险的患者治疗率较低。治疗可能性的增加似乎解释了参保组的生存优势。